Opthea Limited (NASDAQ:OPT) – Analysts at Oppenheimer raised their FY2022 EPS estimates for Opthea in a research report issued to clients and investors on Tuesday, September 21st. Oppenheimer analyst H. Singh now anticipates that the company will post earnings of ($1.12) per share for the year, up from their previous forecast of ($1.40). Oppenheimer also issued estimates for Opthea’s FY2023 earnings at ($1.04) EPS, FY2024 earnings at ($0.88) EPS and FY2025 earnings at $0.80 EPS.
Separately, Zacks Investment Research downgraded shares of Opthea from a “buy” rating to a “hold” rating in a research report on Tuesday, September 14th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $32.18.
An institutional investor recently raised its position in Opthea stock. Victory Capital Management Inc. grew its position in Opthea Limited (NASDAQ:OPT) by 1.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,433,254 shares of the company’s stock after purchasing an additional 25,060 shares during the period. Victory Capital Management Inc. owned approximately 3.27% of Opthea worth $11,381,000 as of its most recent SEC filing. 13.09% of the stock is owned by institutional investors.
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Featured Story: What is the operating income formula?
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.